Revolo Biotherapeutics announced on Jan. 30, 2024 that FDA has granted Orphan Drug Designation to ‘1104, a first-in-class immune-resetting peptide being developed as a potential treatment for eosinophilic esophagitis (EoE). Revolo focuses on developing therapies that reset the immune system to achieve long-term remission for patients with autoimmune and allergic diseases. The original request for ‘1104 was submitted before its Phase IIa EoE study, and the request was amended following the study’s positive results.
